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Abstract
Background: Helicobacter pylori (H. pylori) causes gastritis and intestinal metaplasia (IM) that may
evolve to gastric carcinoma. The objective of this study was to compare the profile of mucins in
the progressive stages of H. pylori infected pre-neoplastic and neoplastic human gastric epithelium.
We used a panel of monoclonal antibodies with well-defined specificities of MUC2, MUC5AC and
MUC6 to characterize the expression pattern of mucins by immunohistochemistry.
Methods: RUT and ELISA were down for H. pylori confirmation. Human gastric biopsy sections
were stained using immunohistochemistry with MUC2, MUC5AC and MUC6 antibodies.
Results: MUC5AC was expressed in the superficial epithelium and the upper part of the gastric
pits. MUC6 expression was detected in the lower part of the gastric glands. MUC2 was expressed
in intestinal metaplasia, mostly in goblet cells. The mucin expression profile in the progressive
stages of H. pylori infected human gastric epithelium allows the identification of intestinal metaplasia,
which is characterized by a decreased expression of the gastric mucins (MUC5AC and MUC6) and
de novo expression of MUC2.
Conclusion: In conclusion, our results suggest that there is altered expression of MUC5AC and
MUC6 together with the aberrant expression of MUC2 in intestinal metaplasia, during the process
of gastric carcinogenesis. The present study indicates that the MUC2 mucin expression pattern is
a reliable marker of intestinal metaplasia, which appears in the context of H. pylori infected
individuals.
Background
Helicobacter pylori colonizes human gastric mucosa and
causes gastritis and intestinal metaplasia (IM), which may
evolve towards gastric carcinoma [1-3]. H. pylori infection
was established as a type I human carcinogen in IARC [4];
it was recently shown that the bacteria are also capable of
inducing gastritis, IM, and gastric carcinoma in Mongo-
lian gerbils [5-8]. In humans, H. pylori also colonizes the
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duodenal mucosa whenever there is gastric metaplasia
[9]. H. pylori infection in human is therefore dependent
on the gastric microenvironment, which is determined to
a large extent by the mucin and carbohydrate composition
of the gastric mucin layer.
Mucins are heavily glycosylated glycoproteins that are the
major components of the mucous viscous gel covering the
surface epithelial tissues [10]. To date, nine distinct epi-
thelial mucin genes (MUC1, 2, 3, 4, 5AC, 5B, 6, 7, and 8)
have been identified [11-21]. In situ hybridization and
immunohistochemical studies have shown that these
mucins are differentially expressed in epithelia with cell
type specificity [21-24]. The normal gastric mucosa shows
cell types specific expression of MUC1, MUC5AC, and
MUC6, with first two mucins found in the superficial epi-
thelium and MUC6 in the deep glands [22,25,26]. MUC6
is mainly expressed in gastric mucosa. The normal gastric
mucosa does not express MUC2 [25,27].
Changes in the expression levels and glycosylation pat-
terns of mucins have been associated with several dis-
eases, including carcinomas [27-31]. In gastric cancer,
alterations in mucin polypeptide have been reported: loss
of expression of MUC5AC [23,26,32], increased mucin
heterogenesity [23]. These observations suggest that
mucin alterations can be regarded as "molecular" markers
of malignant transformation of gastric mucosa. Further
more, a recently published investigation strongly sug-
gested MUC5AC as a putative H. pylari receptor [33,34].
In this present study, we have characterized the pattern of
mucins expression in the progressive stages of H. pylori
infected human gastric carcinoma. We have used a com-
prehensive panel of monoclonal antibodies, with well-
characterized specificities directed to MUC2, MUC5AC
and MUC6 mucins.
Results
Expression pattern of MUC2, MUC5AC and MUC6 mucins 
in normal gastric mucosa
MUC5AC was highly expressed in foveolar epithelium
and mucous neck cells of antrum (> 75%, Fig. 1b; Fig. 3b;
Table 2). Expression of MUC6 was detected in the glands
of the antrum (> 75%, Fig. 1c; Fig. 3c; Table 3) and MUC2
was not detected in normal gastric mucosa (Fig. 1a; Fig.
3a; Table 2).
Immunodetection of mucins in atrophic gastritis
There was expression of MUC5AC in all the cases of
columnar cells (Fig. 1e; Fig. 3b; Table 2). The percentage
of stained cells varied from case to case, in most cases,
there was a trend for higher number of cells expressing
MUC5AC (>75%) in the superficial part of the metaplas-
tic glands than in deep part. MUC6 was detected in
columnar cells (>50%; Fig. 1f; Fig. 3c; Table 2) and MUC2
was not detected in atrophic gastritis (Fig. 1d).
Immunodetection of mucins in intestinal metaplasia
There was decreased level expression of MUC5AC and
MUC6 in all the cases (>50%), both in goblet and in
columnar cells (Fig. 1h, Fig. 2a; Fig. 3b, Fig. 3c; Table 2).
The percentage of stained cells varied from case to case, de
novo expression of intestinal mucin MUC2 was observed
Immunohistochemical staining of MUC2, MUC5AC and  MUC6 mucins in H. pylori infected patients Figure 1
Immunohistochemical staining of MUC2, MUC5AC 
and MUC6 mucins in H. pylori infected patients. a. 
MUC2 staining of normal gastric mucosa (Original magnifica-
tion ×100). b. MUC5AC staining of normal gastric mucosa 
(Original magnification ×100). c. MUC6 staining of normal 
gastric mucosa (Original magnification ×100). d. MUC2 stain-
ing of Atrophic gastritis (Original magnification ×100). e. 
MUC5AC staining of Atrophic gastritis (Original magnifica-
tion ×100). f. MUC6 staining of Atrophic gastritis (Original 
magnification ×100). g. MUC2 staining of Intestinal metapla-
sia (Original magnification ×100). h. MUC5AC staining of 
Intestinal metaplasia (Original magnification ×100).Molecular Cancer 2006, 5:10 http://www.molecular-cancer.com/content/5/1/10
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(>75%), and its expression displayed a diffuse cytoplas-
mic pattern in goblet cells (Fig. 1g; Fig. 3a; Table 2).
Immunodetection of mucins in dysplasia
There was decreased level expression of MUC5AC and
MUC6, than intestinal metaplasia (>50%). MUC5AC and
MUC6 displayed a diffuse cytoplasmic expression pattern
in columnar cells (Fig. 2c; Fig. 2d; Fig. 3d; Fig. 3; Table 2).
MUC2 expression displayed a diffuse cytoplasmic pattern
in goblets cells (>50%, Fig. 2b; Fig 3a; Table 2).
Immunodetection of mucins in carcinoma
MUC5AC and MUC6 expression were frequently
observed in early carcinoma (>50%) than advanced carci-
nomas (>25%). In advanced carcinomas, we observed a
trend for decreased immunoreactivity in deep areas than
in the superficial areas. MUC5AC and MUC6 expressions
were decreased in advanced carcinomas (>25%; Fig. 3a;
Fig. 3b; Fig. 3c; Fig. 2e, Fig. 2f, Fig. 2g; Table 2).
Discussion
In this present study, we have shown that the pattern of
mucins expression in the progressive stages of H. pylori
infected human gastric epithelium. Mucins are expressed
with a cell- and tissue-specific pattern in normal tissue.
Alterations of the expression pattern of mucins have been
described in carcinomas as well as in their precursor
lesions; in the latter, altered mucin carbohydrate and pep-
tide moieties may constitute molecular markers of
increased risk of malignant transformation [27,35,36,38-
40].
In agreement with previous studies reporting the distribu-
tion of mucins in normal stomach, we found MUC5AC is
highly expressed in foveolar cells of antrum, as reported
[26,27,32,37-39]. We also found that MUC6 is expressed
in mucous cells of the neck zone in pyloric glands of the
antrum with similar pattern to that described previously
[22,23,47]. The expression of MUC2 was usually not
detected in normal gastric mucosa as described in the pre-
vious reports [25,27,40].
Intestinal metaplasia is one of the lesions identified in the
cascade of event that precedes the development of gastric
carcinoma [41]. Intestinal metaplasia comprises the
replacement of the gastric mucosa by an epithelium that
resembles histologically the intestinal mucosa. Altered
mucin expression patterns have been observed in H. pylori
infected intestinal metaplasia, including under expression
of MUC5AC and MUC6 and de novo expression of MUC2
mostly in goblet cells [30,48]. These results support the
assumption that the intestinal metaplasia does represent a
differentiation of the mucosa toward a intestinal pheno-
type [42,43].
The decreased expression of MUC5AC and MUC6 mucin
in gastric carcinomas were confirmed in the present study.
The expression of MUC5AC in early gastric carcinoma of
the present series, regardless of the histological type of the
tumors, contrasts with the decreased level expression of
MUC5AC immunoreactivity in almost half of the
advanced carcinomas which suggest that all gastric carci-
nomas retain at least some cells with a gastric phenotype
during the first steps of neoplastic development (26). This
assumption is further supported by the decreased immu-
noreactivity in deep areas compared with superficial areas
Immunohistochemical staining of MUC2, MUC5AC and  MUC6 mucins in H. pylori infected patients Figure 2
Immunohistochemical staining of MUC2, MUC5AC 
and MUC6 mucins in H. pylori infected patients. a. 
MUC6 staining of Intestinal metaplasia (Original magnification 
×100). b. MUC2 staining of dysplasia (Original magnification 
×100). c. MUC5AC staining of dysplasia (Original magnifica-
tion ×100). d. MUC6 staining of dysplasia (Original magnifica-
tion ×100). e. MUC2 staining of carcinoma (Original 
magnification ×100). f. MUC5AC staining of carcinoma (Orig-
inal magnification ×100). g. MUC6 staining of carcinoma 
(Original magnification ×100).
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of the advanced carcinomas. These results are in agree-
ment with previous results showing that gastric cancer
progression is accompanied by alteration of the expres-
sion of several mucin genes [14]. Finally, we observed that
the intestinal mucin MUC2 is expressed in every intestinal
metaplasia, which is a lesion that appears during the proc-
ess of gastric carcinogenesis in the context of H. pylori
infected individuals.
Conclusion
Although H. pylori has been classified as a class I carcino-
gen by the IARC [4] the mechanism of gastric carcinogen-
esis remains poorly understood. In pre-neoplastic gastric
mucosa, the expression of all the three mucin antigens did
not appear to correlate with the severity of inflammation
and H. pylori status. Results from the present study may
suggest that H. pylori infection acts as an initiator of this
carcinogenesis cascade by inducing inflammation and, in
some cases, the subsequent metaplastic change. Intestinal
metaplasia is accompanied by the induction of expression
MUC2 and decreased expression of MUC5AC and MUC6.
These alterations may favor the development of gastric
carcinoma. The present study suggests that MUC2 is a
marker of intestinal metaplasia and may be used for the
early detection of this lesion in H. pylori infected pre-neo-
plastic human gastric epithelium.
Materials and methods
Tissue samples
Fifty nine gastric biopsy specimens and 3 ml of blood
were obtained from Stanley Medical College and Hospi-
tal, Chennai. All biopsy tissue samples were collected after
informed consent. This study was carried out after obtain-
ing clearance from the ethical board of the hospital. All
biopsy specimens were fixed in 10% buffered formalin
and routinely embedded in paraffin wax. 4 µm thin serial
sections were cut and used for immunohistochemistry. H.
pylori infection was confirmed by RUT and ELISA [43].
Hematoxylin and Eosin stained sections were used to clas-
sify gastritis graded according to revised Sydney classifica-
tion [44], gastric tumors according to the classification of
Lauren [45] and WHO classification [46]. We studied 7
cases of normal Human gastric epithelium (7 biopsies),
26 cases of Atrophic gastritis (26 biopsies), 21 cases of
Intestinal metaplasia (21 biopsies), 17 cases of dysplasia
(17 biopsies) and 36 cases of carcinoma in which 21 cases
early carcinoma and 15 cases advanced carcinoma (16
biopsies and 20 surgical specimens).
Monoclonal antibodies
A panel of three monoclonal antibodies was used to deter-
mine the expression of mucins (MUC2, MUC5AC and
MUC6). The specificities, references and dilutions of the
antibodies are listed in Table 1.
Immunohistochemistry
Sections from normal, pre-neoplastic and neoplastic gas-
tric tissues were immuno stained according to Reis et al
[47] with slight modifications. Sections designed for neu-
raminidase treatment were washed twice in phosphate
buffered saline (PBS), pH 7.4 and incubated with neu-
Expression pattern of mucins (MUC2, MUC5AC and MUC6)  in H. pylori infected pre-neoplastic and neoplastic human gas- tric epithelium Figure 3
Expression pattern of mucins (MUC2, MUC5AC and 
MUC6) in H. pylori infected pre-neoplastic and neo-
plastic human gastric epithelium. a. MUC2 expression 
in H. pylori infected pre-neoplastic and neoplastic human gas-
tric epithelium. b. MUC5AC expression in H. pylori infected 
pre-neoplastic and neoplastic human gastric epithelium. c. 
MUC6 expression in H. pylori infected pre-neoplastic and 
neoplastic human gastric epithelium.
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raminidase from clostridium perfringens Type VI (Sigma; St
Louis, MO) diluted in 0.1 M Na-acetate buffer, pH 5.5 to
a final concentration of 0.1 U/ml. The incubation was car-
ried out for 2 h at 37°C and was followed by three wash-
ings in ice-cold PBS. Sections were treated with 0.5%
H2O2 in methanol for 30 min, followed by 20 min of
incubation with rabbit non-immune serum. Sections were
rinsed and incubated with primary antibody (Table 1),
over night at 4°C. The sections were rinsed and incubated
with HRP conjucated rabbit anti-mouse secondary anti-
body (1:100 dilution) for 1 h followed by rinsing with
PBS and developing with 0.05% 3,3'-diaminobenzidine
tetrahydrochloride (DAB) (SRL, Mumbai, India) freshly
prepared in PBS containing 0.1% H2O2. Sections were
counter stained with hematoxylin, dehydrated, and
mounted. All series including positive and negative con-
trols were performed by substitution of the primary mAbs
with immunoglobulins of the same class and at the same
concentration.
Scoring of mucins expression in H. pylori infected pre-
neoplastic and neoplastic human gastric tissues
A semi quantitative approach was used to score the immu-
nostaining of human gastric tissues. The slides were exam-
ined under light microscope, every 100 cells were scored
in five different fields and the results were expressed as
mean percentage. (-), negative; +, few positive cells
(<25%); ++ well-defined areas with positive cells (25–
50%); +++, extensive areas with positive cells (50–75%);
++++, most cells stained (>75%).
Table 1: Specificities, origins and dilutions of the monoclonal antibodies.
Monoclonal antibody Specificity Reference Dilution
PMH1 MUC2 Reis et al [11] Undiluted
CLH2 MUC5AC Reis et al [12] 1:2
CLH5 MUC6 Reis et al [10] 1:2
Table 2: Expression of mucins (MUC2, MUCSAC and MUC6) in H. pylori infected pre-neoplastic and neoplastic human gastric 
epithelium
Stages H. 
pylori
MUC2 Expression MUC5AC Expression MUC6 Expression
N P - + ++ +++ ++
++
- + ++ +++ ++++ - + ++ +++ ++++
Normal 
(n = 7)
7 - n = 7 
(100%)
--- - - -- n  =  2  
(28.6%)
n = 5 
(71.4%)
-- - 1  
(14.3%)
6 
(85.7%)
Atrophic 
gastritis 
(n = 26)
-2 6n  =  2 2  
(84.6%)
n = 4 
(15.4%)
- - - - - 1 (38%) 13 
(50%)
12 
(46.2%)
-- 1  
(3.8%)
15 
(57.7%)
10 
(38.5%)
Intestinal 
metaplas
ia 
(n = 21)
-2 1 - - n  =  9  
(42.9%)
n = 12 
(57.1%)
**
-- 1  
(4.8%)
16 
(76.2%)
**
4 (19%) - - 5 
(23.8%)
14 
(66.7%)
**
2 
(9.5%)
-
Dysplasia 
(n = 17)
-1 7 - n  =  5  
(29.4%)
n = 11 
(64.7%)
n = 1 
(5.9%)
-- 3  
(17.6%
)
10 
(58.8%)
4 
(23.5%)
--3  
(17.6%)
11 
(64.7%)
3 
(17.3%)
-
Carcino
ma 
(n = 36)
-3 6 - 2 2  
(61.1%)
14 
(38.9%)
-- - 2 8  
(77.8%
)
8 
(22.2%)
-- 1 2  
(33.3
%)
17 
(47.2%)
7 
(19.4%)
--
N – negative - (> 5%) negative
P – positive + (5–25%) few positive cells
n – No. of cases ++ (25–50%) well-defined area
+++ (50–75%) extensive area stained
++++ (75–100%) most of the cells stained
**p < 0.00, *p < 0.05 (Significant difference in expression)Molecular Cancer 2006, 5:10 http://www.molecular-cancer.com/content/5/1/10
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Statistics
Data analysis was performed using statistical software
package SPSS 10.0 for windows. The Chi-Square test or
Fisher's exact test was used to analyze differences in fre-
quencies. Spearman's correlation test was used to analyze
correlation between parameters. P < 0.05 was considered
statistically significant.
Abbreviations
DAB – 3,3'-diaminobenzidine tetra hydrochloride; ELISA
– Enzyme-linked immunosorbent assay; HRP – Horserad-
ish peroxidase; IARC – International Agency for Research
on Cancer; IM – Intestinal metaplasia; mAbs – Mono-
clonal antibodies; PBS – Phosphate buffered saline; WHO
– World Health Organization; RUT – Rapid Urea Test.
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